Johnson & Johnson
Rating
Updated: Sep 12, 2026Why Price Moved
Shares declined as institutional investors signifi...
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech s...
Latest News
23 hours ago · benzinga.com
Johnson & Johnson Drug Shows Improved Mania Symptoms in Bipolar PatientsJohnson & Johnson (NYSE:JNJ) on Monday reported topline results from its Phase 3 study evaluating Caplyta (lumateperone) for adults experiencing manic episodes linked to bipolar I disorder.
1 day ago · reuters.com
J&J's Caplyta meets main goal of bipolar mania studyJohnson & Johnson said on Monday its experimental use of Caplyta for bipolar mania met the main goal of a late-stage study, bringing the drug a step closer to expanding beyond its currently approved uses.
2 days ago · 247wallst.com
3 Dividend Stocks Built for Retirement to Buy in SeptemberRetirement portfolios need income that shows up on time, grows faster than inflation, and does not blink during a downturn.
4 days ago · zacks.com
J&J Up 18% in Three Months: Buy, Sell or Hold the Stock?JNJ's growth gets a boost from new drug launches and pipeline wins, but Stelara's patent loss and MedTech headwinds remain key risks.
4 days ago · zacks.com
Johnson & Johnson (JNJ) Increases Yet Falls Behind Market: What Investors Need to KnowIn the most recent trading session, Johnson & Johnson (JNJ) closed at $270.22, indicating a +1.1% shift from the previous trading day.
4 days ago · seekingalpha.com
Johnson & Johnson (JNJ) Presents at Deutsche Bank 2026 Healthcare Summit TranscriptJohnson & Johnson (JNJ) Presents at Deutsche Bank 2026 Healthcare Summit Transcript
4 days ago · marketbeat.com
Johnson & Johnson Sees Path to Double-Digit Growth Despite 2026 Patent CliffJohnson & Johnson NYSE: JNJ Executive Vice President and Chief Financial Officer Joe Wolk said the company sees a path to growth above its previously stated 5% to 7% long-term range, supported by its pharmaceutical pipeline, medical technology portfolio and capital flexibility.
5 days ago · gurufocus.com
J&J Slips as Caplyta Clears a Quality-of-Life TestJohnson and Johnson (JNJ), the pharmaceutical and medical-technology giant, added another potentially important commercial argument for Caplyta, with new late-sta
6 days ago · 247wallst.com
Monthly Paydays vs. Compound Growth: Why JNJ Beats O for Long-Term RetireesRealty Income pays you every month while Johnson and Johnson barely clears 2% yield, yet one of these retirement staples is quietly demolishing the other where it counts most for a 20-year income plan.
6 days ago · defenseworld.net
Johnson & Johnson $JNJ Shares Sold by HighTower Advisors LLCHighTower Advisors LLC decreased its stake in shares of Johnson and Johnson (NYSE: JNJ) by 5.6% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The fund owned 9,892,767 shares of the company's stock after selling 591,434 shares during the period. Johnson and Johnson comprises about 2.4%
Analyst Summary
Add to Watchlist
Select watchlists to add or remove JNJ